Literature DB >> 10924731

Redox status of plasma homocysteine and other plasma thiols in stroke patients.

A Andersson1, B Hutlberg, A Lindgren.   

Abstract

Despite the growing evidence that plasma homocysteine is a cardiovascular risk factor, the mechanism behind the vascular injuries is still unknown. Studies are difficult as a result of the fact that little is known about the formation of different homocysteine species in vivo. Since extracellular glutathione and cysteine may influence the formation of different homocysteine species, we have in the present study investigated the different fractions of homocysteine and their relation to the different fractions of glutathione and cysteine in stroke patients and control subjects. We found a ratio of about 32-33% between reduced and total plasma glutathione concentrations and 2.6 3.0% between reduced and total plasma cysteine concentrations both in patients and in healthy control subjects. We noted an elevated concentration of total plasma homocysteine in stroke patients, but no difference in the ratio between reduced and total plasma homocysteine concentrations in patients and control subjects (mean value 1.20 and 1.10%, respectively). However, in a subgroup of patients with higher concentrations of total plasma homocysteine, we observed a significantly lower ratio of reduced to total plasma homocysteine compared to a subgroup of patients with lower concentration of total plasma homocysteine. A low reduced/total ratio of plasma homocysteine in combination with elevated plasma homocysteine concentrations might reflect an increased pro-oxidant activity in plasma from these patients. Thus, increased pro-oxidant activity in plasma might be one factor, besides genetic and nutritional factors, that could explain hyperhomocysteinemia. Since substantial evidence indicates that progression of atherosclerosis is related to enhanced pro-oxidant activity, the premature vascular disease associated with increased plasma homocysteine concentration might be as a result of increased pro-oxidant activity and the elevated plasma homocysteine concentration may only reflect the increased oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10924731     DOI: 10.1016/s0021-9150(99)00418-9

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  5 in total

1.  Harnessing Redox Cross-Reactivity To Profile Distinct Cysteine Modifications.

Authors:  Jaimeen D Majmudar; Aaron M Konopko; Kristin J Labby; Christopher T M B Tom; John E Crellin; Ashesh Prakash; Brent R Martin
Journal:  J Am Chem Soc       Date:  2016-02-05       Impact factor: 15.419

2.  Plasma biomarkers of oxidative stress and genetic variants in age-related macular degeneration.

Authors:  Milam A Brantley; Melissa P Osborn; Barton J Sanders; Kasra A Rezaei; Pengcheng Lu; Chun Li; Ginger L Milne; Jiyang Cai; Paul Sternberg
Journal:  Am J Ophthalmol       Date:  2011-10-29       Impact factor: 5.258

3.  Clinical assay of four thiol amino acid redox couples by LC-MS/MS: utility in thalassemia.

Authors:  Jung H Suh; Robert Kim; Burcu Yavuz; Daniel Lee; Ashutosh Lal; Bruce N Ames; Mark K Shigenaga
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-07-02       Impact factor: 3.205

4.  Role of SH levels and markers of immune response in the stroke.

Authors:  Maria Musumeci; Stefano Sotgiu; Silvia Persichilli; Giannina Arru; Silvia Angeletti; Maria Laura Fois; Angelo Minucci; Salvatore Musumeci
Journal:  Dis Markers       Date:  2013-08-20       Impact factor: 3.434

5.  Impact of glutathione on acute ischemic stroke severity and outcome: possible role of aminothiols redox status.

Authors:  Marina Yurievna Maksimova; Alexander Vladimirovich Ivanov; Edward Danielevich Virus; Ksenya Alexandrovna Nikiforova; Fatima Ramazanovna Ochtova; Ekaterina Taymurazovna Suanova; Maria Petrovna Kruglova; Mikhail Aleksanrovich Piradov; Aslan Amirkhanovich Kubatiev
Journal:  Redox Rep       Date:  2021-12       Impact factor: 4.412

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.